In each case, drug-rHDL treatment increased SR-BI+ cancer cell cytotoxicity versus free drug with the added benefit, as reported by Ding et al. (2014), of diminishing undesired cytotoxicity against cells with limited SR-BI expression. The gene discussed is SCARB1; the disease is cancer.